Genetic Therapy ; methods ; trends ; Genomics ; methods ; trends ; Humans ; MicroRNAs ; genetics ; Neoplasms ; genetics ; therapy ; Phenotype ; Systems Biology ; methods ; trends

Objective: To study the effect and contribution of health investment to economic growth as well as the regional differences among eastern, central and western China. Methods: Based on the provincial panel data from 1997 to 2010, fixed effects model was established to empirically analyze the relationship between health investment and economic growth. Results: Health Investment has significant in promoting economic growth, while significant regional differences still exist, showing the decreasing order of eastern、 central and western China. Conclusion:While strengthening the regional medical health level of investment, it is needed to give preferential policies to the backward central and western regions, so that the differences between regional economic growth and physical condition of residents can be reduced while realizing health investment stimulating economic growth.

Comments concerning Meta analysis for relationship between peroxisome proliferator activated receptor gamma Pro12Ala polymorphism and type 2 diabetes susceptibility in different cohorts in this mini review were given. The comments pointed out existent problems and presented suggestions for genetic analysis of diseases in Chinese populations.
Asian Continental Ancestry Group ; genetics ; Diabetes Mellitus, Type 2 ; genetics ; Genetic Predisposition to Disease ; Humans ; PPAR gamma ; genetics ; Polymorphism, Genetic

China ; Genes, Neoplasm ; Genome, Human ; Genome-Wide Association Study ; methods ; Humans ; Neoplasms ; genetics ; Polymorphism, Single Nucleotide

DNA Methylation ; DNA, Neoplasm ; genetics ; Genomics ; trends ; Human Genome Project ; Humans ; Neoplasms ; genetics ; Research

Sorafenib,a novel oral multikinase inhibitor,targts on serine/threonine kinase and tyrosine kinases receptor of the tumor cells and vasculature.So Sorafenib can inhibit the tumor cell proliferation and revascularization.400 mg sorafenib administered twice a day is chosen as the recommended dosage for several phase Ⅰ studies,and it shows broad-spectrum antitumor activity in renal cancer,hepatocellular carcinoma,melanoma and non-small-cell lung cancer(NSCLC)in phase Ⅱ and Ⅲ clinical trials.Now FDA has approved the usage of sorafenib in renal cancer therapy.

Effective management for hypertension in renal diseases should be carried out according to the principles of 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension.The important role of kidney in the classification of hypertension,the corresponding therapy,the set of the target blood pressure,the choice of antihypertensive agents and combination therapy should be focused.Comprehensive approaches should be used for the treatment of hypertension in renal diseases to protect the target organs(including the kidney).Appropriate prevention and management strategies for hypertension in renal diseases should be disseminated and optimized.

This review comments the status quo, especially the major problems, of the genetic analysis of the complex diseases, provides some possible solutions, and explores the further development trends in this field.
Genetic Testing ; Humans

Cell Movement ; drug effects ; Chemokine CXCL12 ; genetics ; metabolism ; pharmacology ; physiology ; Humans ; Neoplasm Invasiveness ; physiopathology ; Neoplasm Metastasis ; physiopathology ; Neoplasms ; metabolism ; Neovascularization, Pathologic ; physiopathology

Antigens, Neoplasm ; genetics ; metabolism ; Breast Neoplasms ; enzymology ; genetics ; metabolism ; DNA Topoisomerases, Type II ; genetics ; metabolism ; DNA-Binding Proteins ; genetics ; metabolism ; Female ; Gene Expression Regulation, Neoplastic ; physiology ; Humans